Cefuroxime axetil
 | |
| Systematic (IUPAC) name | |
|---|---|
|
1-Acetoxyethyl (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
| Clinical data | |
| Trade names | Zinnat, Ceftin, Ceftum |
| Legal status |
|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | well absorbed |
| Metabolism | Cefuroxime is not metabolized, Axetil is metabolized to acetaldehyde and acetic acid. |
| Excretion | Urine |
| Identifiers | |
| PubChem | CID 6321416 |
| ChemSpider | 4882027 |
| ChEMBL | CHEMBL1095930 |
| Synonyms | Cefuroxime 1-acetoxyethyl ester |
| Chemical data | |
| Formula | C20H22N4O10S |
| Molar mass | 510.475 g/mol |
| |
| |
Cefuroxime axetil is a second generation oral cephalosporin antibiotic. It was discovered by Glaxo now GlaxoSmithKline and introduced in 1987 as Zinnat.[1] It was approved by FDA on Dec 28, 1987.[2] It is available by GSK as Ceftin in US[3] and Ceftum in India.[4]
It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.[5] The activity depends on in vivo hydrolysis and release of cefuroxime.
See also
References
- ↑ "Our history - About GSK". GlaxoSmithKline.
- ↑ http://www.drugs.com/monograph/cefuroxime-axetil.html
- ↑ https://www.gsksource.com/gskprm/en/US/adirect/gskprm?cmd=ProductsByName#C
- ↑ "Our products". GlaxoSmithKline.
- ↑ Walter Sneader. Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, December 14, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.